Maiwald acted as legal advisor to Royalty Pharma in connection with an innovative funding agreement totaling up to $2 billion with Revolution Medicines. The transaction includes up to $1.25 billion in synthetic royalty funding and a secured term loan of up to $750 million.
This strategic partnership enables Revolution Medicines to independently advance and globally commercialize daraxonrasib, a potentially game-changing RAS(ON) inhibitor currently in Phase 3 clinical trials for pancreatic cancer and non-small cell lung cancer (NSCLC). If successful, daraxonrasib could become the first targeted therapy to inhibit all major forms of RAS — one of the most common drivers of human cancers.
The agreement highlights Royalty Pharma’s ability to deliver flexible, large-scale capital solutions to innovative biotech companies while allowing them to retain full control over development and commercialization.
We are proud to have supported Royalty Pharma on this milestone transaction. This text is a summary of an article published by Royalty Pharma. The full text of the article is available here.
